数据非依赖采集质谱用于识别膜性肾病靶抗原
该回顾性队列研究对64例肾活检标本(含31例健康对照、5例PLA2R相关MN、23例PLA2R阴性MN、5例其他肾小球病)行激光捕获显微切割质谱(LCM/MS),并整合数据非依赖采集(DIA)技术。结果显示DIA较传统DDA显著增加 glomerular 蛋白鉴定数并提高PLA2R阴性MN的抗原检出率,为MN的抗原分类和机制理解提供支持。
要点
- DIA较DDA增加健康肾小球蛋白鉴定数(约3800 vs 约1200)。
- DIA使PLA2R阴性MN抗原检出率从46%提高至83%。
- PLA2R-MN肾小球中PLA2R、IgG4及补体蛋白显著富集。
核心结论
- LCM/MS联合DIA较LCM/MS联合DDA能识别更多靶抗原,可能增进对MN疾病机制的理解。
研究设计与样本
- 回顾性队列研究,使用肾活检残余标本,共64例个体,包括31例健康对照、5例PLA2R相关MN、23例PLA2R阴性MN和5例其他肾小球疾病。
主要发现
- PLA2R-MN标本肾小球中PLA2R、IgG4和补体蛋白显著富集,提供补体激活的分子证据。
- DIA在健康肾小球中鉴定约3800种蛋白,而DDA约1200种。
- DIA可检测除NELL1外的所有已知抗原在正常肾小球中的表达。
- DIA将PLA2R阴性MN的抗原检出率从46%提高至83%。
关键数值与推荐
- DIA较DDA增加健康肾小球蛋白鉴定数(约3800 vs 约1200)。
- PLA2R阴性MN抗原检出率DIA为83%,DDA为46%。
临床怎么用
- LCM/MS联合DIA可作为检测MN靶抗原的更敏感工具,辅助抗原分类。
- 该技术有望为MN的临床诊断和分类提供信息。
局限性
- 回顾性设计。
- 样本量有限。
- 未鉴定新抗原。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: In recent years, the strategy of using laser capture microdissection and mass spectrometry (LCM/MS) has expanded the landscape of antigens associated with membranous nephropathy (MN). Specific associations with phenotypes, diseases, and sometimes reversible triggers led to an antigen-based classification of MN, informing precision medicine and highlighting the potential value of routine use of proteomics in classifying MN. This study reproduces and further improves the original LCM/MS for antigen detection in MN. STUDY DESIGN: Retrospective cohort study using residual material from kidney biopsies. SETTING & PARTICIPANTS: We applied LCM/MS to kidney biopsy specimens from 64 individuals, including 31 healthy controls; 5 with M-type phospholipase A2 receptor (PLA2R)-associated MN; 23 with PLA2R-negative MN; and 5 individuals with other glomerular diseases. PREDICTOR: Proteomic analysis of microdissected glomeruli. OUTCOME: Protein abundance and C3 fragments in PLA2R-MN specimens versus controls; identification of target antigens in PLA2R-negative MN. ANALYTICAL APPROACH: The technique of LCM/MS was expanded by integrating a data-independent acquisition (DIA) approach to enable the identification and quantification of peptides of varying abundance. RESULTS: We observed significant enrichment in PLA2R, IgG4, and complement proteins, providing molecular evidence for complement activation in glomeruli from patients with PLA2R-MN. Compared with conventional data-dependent acquisition (DDA), DIA increased the number of glomerular proteins (∼3,800 vs ∼1,200) identified in healthy glomeruli, allowed the detection of all known antigens except NELL1 in normal glomeruli, and increased the detection rate of antigens from 46% to 83% in PLA2R-negative MN. LIMITATIONS: Retrospective design; sample size; no identification of novel antigens. CONCLUSIONS: An integrative approach combining LCM/MS and DIA enabled identification of more target antigens than LCM/MS with DDA, potentially informing our understanding of disease mechanisms in MN. PLAIN-LANGUAGE SUMMARY: Membranous nephropathy is an autoimmune kidney disease characterized by circulating autoantibodies that recognize antigens in podocytes or in the glomerular basement membrane. To date, more than 10 different antigens have been identified, with specific associations with various etiologies and potential impact on management. In this study, proteomic analyses were implemented on glomeruli microdissected from kidney biopsies in patients with membranous nephropathy and appropriate controls. The original technique of proteomic analysis developed by Sethi and coworkers was expanded by applying a specific and more sensitive mass spectrometry method (data-independent acquisition) combined with bioinformatics analysis. We showed that this approach is a powerful tool to detect target antigens, and it may provide insights into disease mechanisms, with the potential to inform clinical diagnosis and classification of membranous nephropathy.
引用
- Morelle J, Aydin S, Debiec H, et al. Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy. Am J Kidney Dis. 2025. PMID: 40058725. doi:10.1053/j.ajkd.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。